TP53 and central nervous system cancer: The experimental results show that the simulated structural phosphorylation P53 constructor (Ad-P53-18D20D) at Thr18 and Ser20 can induce G1 stagnation of normal cell strains after exogenous non-phosphorylation P53 (Ad-P53) administration, indicating that the phosphorylation of P53 at Thr18 and Ser20 is enough to induce P53-mediated glioma cell apoptosis (Nakamizo et al., 2008).